Sutacimig  (Synonyms: HMB-001)

Sutacimig (HMB-001) is a humanized antibody of the (H-γ4_L-κ)_(H-γ4_L-κ) format that targets FⅦa/TREML1. One arm of Sutacimig binds to endogenous FVIIa, thereby prolonging the half-life of FVIIa and increasing its accumulation in the bloodstream, while the other arm binds to TLT-1, which is exclusively expressed on the surface of activated platelets. This localizes endogenous FVIIa to activated platelets, further enhancing the activity of FVIIa. Sutacimig enhances Thrombin generation, fibrin formation, and the formation of stable fibrin-platelet networks at sites of vascular injury. Sutacimig can be used in studies related to Glanzmann thrombasthenia^[1][2][3].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

F7 & TREML1

One arm of Sutacimig binds endogenous FVIIa, thereby extending the half-life of FVIIa and increasing its accumulation in the blood circulation. The other arm binds TLT-1, which is exclusively expressed on the surface of activated platelets, thus localizing endogenous FVIIa to activated platelets, enhancing the activity of FVIIa, boosting thrombin generation and fibrin formation downstream of platelet activation sites, and promoting the formation of a stable fibrin-platelet meshwork, which is essential for achieving hemostasis^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2155  [NCBI] & 340205  [NCBI]

P08709 & Q86YW5

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

2933972-64-4

Liquid

colorless

[Sutacimig]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG4-kappa

• 
  Immobilized Coagulation factor VII/F7 Protein, Human (HEK293, His, HY-P78763) can bind Sutacimig. The EC₅₀ for this effect is 10.01 ng/mL.
• 
  Flow cytometric analysis of 1.5×10⁶ Jurkat cells with Sutacimig (HY-P991029, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Saultier P, et al. Sutacimig, a novel bispecific antibody for prophylactic treatment of glanzmann thrombasthenia: Analysis of a Phase 2 study[J]. 2025.

  [2]. Saultier P, et al. A Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sutacimig for prophylaxis in glanzmann thrombasthenia: A trial in progress[J]. Blood, 2025, 146: 8232.

  [3]. INN Proposed List 131. 11 August 2024.